Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 4/20 | 0.53 |
| ▸ | GRM5 | P41594 | 4/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30269885 | 0.89 | GPR119 (0.51) | GRM1GRM5GPR119GBA1KIT | |
| SCHEMBL28369668 | 0.89 | GPR119 (0.51) | GRM1GRM5GPR119GBA1KIT | |
| SCHEMBL4486545 | 0.89 | GRM1 (0.65) | GRM1GRM5GPR119GBA1NAMPT | |
| SCHEMBL29774060 | 0.89 | GRM1 (0.65) | GRM1GRM5GPR119GBA1NAMPT | |
| SCHEMBL17667439 | 0.81 | ALDH1A1 (0.44) | NAMPTCYP11B2 | |
| SCHEMBL1240331 | 0.79 | GRM5 (0.53) | GRM1GRM5KITNAMPTPDK4 | |
| SCHEMBL30308750 | 0.78 | GRM5 (0.58) | GRM1GRM5GPR119KITNAMPT | |
| SCHEMBL17722891 | 0.78 | GRM5 (0.58) | GRM1GRM5GPR119POLBPDK4 | |
| SCHEMBL25087234 | 0.78 | GBA1 (0.44) | GRM1GRM5GPR119GBA1KIT | |
| SCHEMBL25231247 | 0.77 | GBA1 (0.49) | GRM1GRM5GPR119GBA1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-05 | — | — | US | disclosed |
| EP-3006438-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014192868-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | DRD2, DRD4, DRD1 | GRM1 22/4885GRM5 202/4885GPR119 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.